Marcin Kortylewski
Professor
Immuno-Oncology
Beckman Research Institute
United States of America
Biography
Dr. Kortylewski received his Ph.D. in molecular biology from the University School of Medical Sciences in Poznan (Poland). He then completed two postdoctoral fellowships: in cancer biology at the Institute of Biochemistry (Aachen, Germany) and in tumor immunology at H. Lee Moffitt Cancer Center (Tampa, FL). As an independent investigator, his team develops oligonucleotide-based STAT3 inhibitors for immunotherapy of human cancers. The first generation siRNA-based molecule currently undergoes safety and tolerability studies assisting IND filing. Research from Dr. Kortylewski’s laboratory has earned notable funding from major federal and private sources, including the National Institutes of Health/National Cancer Institute, the Department of Defense — Prostate Cancer Program, ThinkCure, Margaret E. Early Medical Research Trust, STOP CANCER and the Prostate Cancer Foundation.
Research Interest
ancer Immunotherapy, Oligonucleotide Therapeutics, siRNA, Signal Transduction, Tumor Immunology, Immuno-Oncology,
Publications
-
Curran E, Chen X, Corrales L, Kline DE, Dubensky TW, Duttagupta P, Kortylewski M, Kline J. STING pathway activation stimulates potent immunity against acute myeloid leukemia. Cell reports. 2016 Jun 14;15(11):2357-66.
-
Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan YC, Liu Z, Jones J, D’Apuzzo M. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. Journal of Leukocyte Biology. 2017 May 22:jlb-3MA1016.
-
Kortylewski M, Moreira D. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunology, Immunotherapy. 2017:1-0.
